Know Cancer

or
forgot password

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors


Phase 1
18 Years
N/A
Not Enrolling
Both
ADVANCED SOLID TUMORS

Thank you

Trial Information

Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM01183 in Patients With Advanced Solid Tumors


This is a phase I, multicenter, open-label, dose escalating clinical and pharmacokinetic
study of PM01183 for patients with advanced solid tumors to identify the dose limiting
toxicities (DLTs), determine the maximum tolerated dose (MTD) and the recommended dose (RD)
of PM01183 administered every three weeks intravenously (i.v.) over one hour to patients
with advanced solid tumors and to preliminarily determine the pharmacokinetics of PM01183,
to evaluate the antitumor activity of PM01183 and the safety and tolerability of PM01183.
Besides this study will evaluate the pharmacogenomics in tumor samples and peripheral white
blood cells (PWBCs) of patients exposed to PM01183 at the RD in order to assess potential
markers of response and/or resistance.


Inclusion Criteria:



1. Voluntary written informed consent of the patient obtained before any study-specific
procedure.

2. Patients with histologically/cytologically confirmed diagnosis of advanced solid
tumors refractory to standard therapy or for whom no standard therapy exist
(excluding primary central nervous system tumors).

3. Age ≥ 18 years.

4. Patients with measurable or non-measurable disease according to RECIST.

5. Patients entered at the expansion cohort of the RD must have:

- Measurable disease according to RECIST and/or, evaluable disease by serum
markers in the case of prostate and ovarian cancer [according to the
Prostate-Specific Antigen Working Group Recommendations (PSAWGR) and the
Gynecologic Cancer Intergroup (GCIG) specific criteria, respectively].

- Confirmed progressive disease after last therapy, before study initiation.

- Available tumor samples (if pharmacogenomic study consented).

6. Recovery from any drug-related adverse event derived from any previous treatment,
excluding alopecia and grade ≤ 1 asymptomatic peripheral neuropathy according to the
National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE)
v.3.0.

7. Laboratory values within seven days prior to first infusion:

- Platelet count ≥ 100 x109/l, hemoglobin > 9 g/dl (patients can be transfused as
clinically indicated prior to study entry) and absolute neutrophils count (ANC)
≥ 1.5 x109/l.

- Alkaline phosphatase ≤ 2.5 x the upper limit of normality (ULN)

- Aspartate aminotransferase (AST) ≤ 2.5 x ULN.

- Alanine aminotransferase (ALT) ≤ 2.5 x ULN.

- Total bilirubin ≤ ULN. f) Calculated creatinine clearance: ≥ 40 ml/min
(calculated using the Cockcroft and Gault formula).

- Albumin ≥ 2.5 g/dl.

- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

8. Women of childbearing potential must have a negative serum pregnancy test before
study entry. Both men and women must agree to use a medically acceptable method of
contraception throughout the treatment period and for 6 months after discontinuation
of treatment. Acceptable methods of contraception include: intrauterine conceptive
device (IUD), oral contraceptives, subdermal implant and double barrier (condom with
a contraceptive sponge or contraceptive suppository).

Exclusion Criteria:

1. Pregnant or lactating women.

2. Less than three weeks from radiation therapy (six weeks in case of extensive prior
radiotherapy) or last dose of hormonal therapy, biological therapy or chemotherapy
(six weeks in case of nitrosoureas, mitomycin C, trastuzumab, bicalutamide or
high-dose chemotherapy).

3. Evidence of progressive Central Nervous System (CNS) metastases or any symptomatic
brain or leptomeningeal metastases.

4. Patients for whom non-standard surgery approach may result in tumor free survival or
significant palliation.

5. Other relevant diseases or adverse clinical conditions:

- Increased cardiac risk: symptomatic and/or medication requiring congestive heart
failure or clinically relevant valvular heart disease or unstable angor pectoris
or myocardial infarction within 12 months before inclusion in the study, or ≥
grade 1 arrhythmia or any grade requiring treatment, or uncontrolled arterial
hypertension (≥ 160/100 mmHg) despite optimal medical therapy.

- History of significant neurological or psychiatric disorders.

- Active infection.

- Significant non-neoplastic liver disease (e.g., cirrhosis, active chronic
hepatitis).

- Immunocompromised patients, including those known to be infected by human
immunodeficiency virus (HIV).

- Any other major illness that, in the investigator's judgment, will substantially
increase the risk associated with the patient's participation in this study.

6. Limitation of the patient's ability to comply with the treatment or to follow-up at a
participating protocol. Patients registered on this trial must be treated and
followed at a participating center.

7. Prior treatment with any investigational product in the period ≥ 5 half-lives of the
investigational compound prior to the first infusion.

8. Known hypersensitivity to any of the components of the drug product.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To identify the dose limiting toxicities (DLTs), determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 administered every three weeks intravenously (i.v.) over one hour to patients with advanced solid tumors.

Outcome Time Frame:

Along the study

Safety Issue:

Yes

Principal Investigator

Mark Ratain, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Cancer Research Center. University of Chicago Hospitals.

Authority:

United States: Food and Drug Administration

Study ID:

PM1183-A-001-08

NCT ID:

NCT00877474

Start Date:

March 2009

Completion Date:

June 2011

Related Keywords:

  • Advanced Solid Tumors
  • PM01183
  • Solid tumors
  • PharmaMar USA
  • Neoplasms

Name

Location

Cancer Research Center. University of Chicago Hospitals.Chicago,, Illinois  60637